In line with the above observation, LSD1 inhibitors (LSD1i) including IMG-7289, CC-90011, and SP2577 are currently undergoing clinical study for treatment of cancers, such as AML, SCLC, prostate cancer, and Ewing sarcoma28,29. This evidence concerns the gene KDM1A and small cell lung carcinoma.